News
Public · Published
Radiopharm Theranostics and FDA Agree on Design of Phase 3 RAD101 Trial for Brain Metastases
Radiopharm Theranostics agreed with the US Food and Drug Administration on the design of a pivotal Phase 3 trial of RAD101, an imaging agent for patients with uncertain brain metastases after radiotherapy. The company expects to enrol 280 patients and measure the agent's sensitivity and specificity against a reference standard.
Published:
Updated:
What happened
Radiopharm Theranostics agreed with the US Food and Drug Administration on the design of a pivotal Phase 3 trial of RAD101, an imaging agent for patients with uncertain brain metastases after radiotherapy. The company expects to enrol 280 patients and measure the agent’s sensitivity and specificity against a reference standard.
Confirmed
Global impact / market context
Agreement on the trial design may reduce uncertainty about the evidence regulators expect, helping Radiopharm advance RAD101 toward a possible approval decision. If the trial succeeds and the agent is adopted, revenue could follow, while trial spending and development costs will come first.
Analyst inference
This remains a clinical-development story, not a confirmed commercial launch: RAD101 must still be evaluated in the planned Phase 3 trial. The article gives no trial timing, results, cost, funding details, or approval outlook, so near-term value depends on execution and evidence.
Analyst inference
What to watch
- Watch for enrolment progress toward the planned 280 patients and whether the trial reports results for both sensitivity and specificity against its stated reference standard. Analyst inference
- Look for any announced trial start, completion timing, or spending details, which would clarify how long Radiopharm must fund development before results become available. Analyst inference
- Check whether later company updates describe RAD101’s performance in distinguishing recurrent cancer from treatment effects, the clinical problem identified in the article. Analyst inference